Cellectis Files 6-K Report with Press Release
Ticker: CLLS · Form: 6-K · Filed: Apr 22, 2024 · CIK: 1627281
| Field | Detail |
|---|---|
| Company | Cellectis S.A. (CLLS) |
| Form Type | 6-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, press-release
TL;DR
Cellectis dropped a 6-K filing today, likely with news in the attached press release. Check it out.
AI Summary
Cellectis S.A. filed a Form 6-K on April 22, 2024, to report a press release dated April 22, 2024. The filing indicates that Cellectis is a foreign private issuer and files annual reports under Form 20-F. The press release is the primary exhibit, suggesting it contains the material information for this filing.
Why It Matters
This filing provides an update from Cellectis S.A., a biotechnology company, which could contain significant news impacting its stock and future operations.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain material updates, but without the content of the press release, the specific risks are unknown.
Key Players & Entities
- Cellectis S.A. (company) — Registrant
- April 22, 2024 (date) — Filing date and press release date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release dated April 22, 2024, as required for foreign private issuers.
What is the filing date of this report?
This report was filed on April 22, 2024.
Does Cellectis S.A. file annual reports under Form 20-F or 40-F?
Cellectis S.A. files annual reports under cover of Form 20-F.
What is the exhibit number and title associated with this filing?
The exhibit number is 99.1 and the title is 'Press Release dated April 22, 2024'.
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered at 8, rue de la Croix Jarry, 75013 Paris, France.
Filing Stats: 158 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-04-22 16:35:09
Filing Documents
- f6k_042224.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-24-002128.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellectis S.A. (Registrant) Date: April 22, 2024 /s/ Andr Choulika Andr Choulika Chief Executive Officer